Risk/benefit profile of arsenic trioxide Journal Article
| Authors: | Rust, D. M.; Soignet, S. L. |
| Article Title: | Risk/benefit profile of arsenic trioxide |
| Abstract: | Approximately 20%-30% of patients with acute promyelocytic leukemia (APL) who are treated with the current standard all-trans retinoic acid and anthracycline-based chemotherapy regimen suffer relapse. In the mid-1990s, studies from China reported the effective use of arsenic trioxide in achieving complete remission in patients with APL. In the United States, a multicenter trial of this agent in 40 patients with relapsed APL following conventional therapy confirmed the positive safety and efficacy outcomes of a smaller 12-patient pilot study. Common adverse events were hyperleukocytosis, APL differentiation syndrome, prolonged QT interval on electrocardiogram, skin rash, and hyperglycemia. |
| Keywords: | drug efficacy; drug safety; risk benefit analysis; antineoplastic agents; conference paper; neoplasm recurrence, local; risk assessment; hyperglycemia; rash; arsenic trioxide; arsenicals; leukemia, promyelocytic, acute; oxides; acute myeloblastic leukemia; remission; anthracycline derivative; leukocytosis; retinoic acid; china; acute promyelocytic leukemia; qt interval; all-trans retinoic acid; hyperleukocytosis; long qt syndrome; humans; human; priority journal; apl differentiation syndrome |
| Journal Title: | The Oncologist |
| Volume: | 6 |
| Issue: | Suppl. 2 |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2001-04-01 |
| Start Page: | 29 |
| End Page: | 32 |
| Language: | English |
| PUBMED: | 11331438 |
| PROVIDER: | scopus |
| DOI: | 10.1634/theoncologist.6-suppl_2-29 |
| DOI/URL: | |
| Notes: | Presented at Scientific Roundtable on Arsenic Trioxide: Scientific and Clinical Progress; 2000 Jul 19; New York, NY -- Export Date: 21 May 2015 -- Source: Scopus |
